Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience (NASDAQ:SKYE) and maintained a $14 price target.
June 17, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Skye Bioscience and maintained a $14 price target, indicating strong confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $14 by a reputable analyst suggests positive sentiment and confidence in Skye Bioscience's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100